Identification of intratumoral and peripheral T-cell receptor (TCR) repertoire features associated with acquired (Ar) and primary (Pr) resistance to immune checkpoint inhibitors (ICI).

Authors

null

Sofia Genta

Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

Sofia Genta , Shirin Soleimani , Xuan Li , Stephanie Pedersen , Alisa Nguyen , Albiruni Ryan Abdul Razak , Samuel Saibil , Marcus O. Butler , Philippe L. Bedard , Tong Zhang , Ming Sound Tsao , Ben X Wang , Nittusha Singaravelan , Andrea Covelli , John R. de Almeida , Aaron Richard Hansen , Lawson Eng , Trevor J. Pugh , Lillian L. Siu , Anna Spreafico

Organizations

Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada, University of Toronto, Toronto, ON, Canada, Princess Margaret Cancer Centre, Toronto, ON, Canada, Ontario Cancer Institute, Princess Margaret Cancer Centre, Toronto, ON, Canada, University Health Network, Toronto, ON, Canada, Princess Margaret Cancer Centre, Ontario Institute for Cancer Research, University of Toronto, Toronto, ON, Canada

Research Funding

Conquer Cancer Foundation of the American Society of Clinical Oncology
Conquer Cancer Foundation of the American Society of Clinical Oncology, University of Toronto Institutional Funding, Dr. Siu's BMO Chair in Precision Genomics

Background: Our understanding of the mechanisms of Pr vs Ar to ICI is limited. T-cells are the main driver of ICI response. Therefore, interrogation of intratumoral and peripheral TCR repertoire could expand our comprehension of T-cell mediated factors underlying Pr and Ar to ICI. Methods: The Immune Resistance Interrogation Study (NCT04243720) is a prospective study to comprehensively characterize cancers with Pr vs Ar to ICI (Genta et. al., ASCO 2021). We conducted TCRβ capture and sequencing (CapTCR-seq) on paired tumors and blood samples collected from solid tumor patients (pts) at the time of progression on ICI. Tumor and peripheral TCR diversities were calculated for each pt. Grouping Lymphocyte Interactions by Paratope Hotspots (GLIPHII) was used to investigate the potential antigen specificities of intratumoral T-cells. Pt-derived TCRs were pooled with TCRs from a public database with known antigen specificities (TCRdb). GLIPHII grouped pt-derived and external TCRs with similar CDR3s (hypervariable TCR domains) in clusters. The clusters were then converted into a network model representing unique TCRs as nodes. The number of connections between each pt-derived TCR and similar TCRs from TCRdb was defined as node degree. Comparisons between groups were done using Mann Whitney U Test. Results: As of February 2023, 75 pts (45 Pr/30 Ar) were enrolled. CapTCR-Seq in blood and tumor samples was completed in 13 pts (7Pr/6Ar) with the following characteristics: median age 57 years (26-77), 8 male (62%), 8 melanoma (62%), 4 HNSCC (31%), and 1 GE-junction (7%). 5 pts received PD-1/PD-L1 inhibitor monotherapy (38%), 8 pts ICl-based combinations (62%). No significant differences in intratumoral (10.3 [1.3-34.2] vs 15.2 [6.6-32.4] p=0.29) and peripheral (145.5 [65.3- 521.9] vs 136.0 [35.1-474.4] p=0.53) Shannon diversities were observed between Pr and Ar. Twelve of 13 (92%) pts had at least 1 intratumoral TCR clustered with TCRdb derived TCRs. A higher median of node degree was observed in non-melanoma tumors (5.5 [2-12] vs 2.0 [1-4] p=0.03). A trend towards a higher median of node degree was reported in Ar vs Pr (5.5 [1-12] vs 2.0 [1-4] p=0.07 ). Some of the GLIPHll-identified clusters contained TCRs derived from multiple Ar pts. Conclusions: lntratumoral TCRs from non-melanoma and Ar pts had a higher node degree, indicating similarity with a larger number of external TCRs. The difference between Pr and Ar was not significant, potentially due to the small sample size. Similar TCRs belonging to the same GLIPHll-identified clusters were shared among multiple Ar pts. If confirmed in a larger dataset, these findings might suggest the existence of a set of intratumoral exhausted T-cells shared by multiple pts contributing to Ar but not to Pr. Pt accrual, sample collection and analysis are ongoing. Additional data will be presented.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Breakthrough

Session Type

Poster Session

Session Title

Poster Session B

Track

Gastrointestinal Cancer,Gynecologic Cancer,Head and Neck Cancer,Quality of Care,Genetics/Genomics/Multiomics,Healthcare Equity and Access to Care,Healthtech Innovations,Models of Care and Care Delivery,Population Health,Viral-Mediated Malignancies

Sub Track

Immunotherapies

Citation

JCO Global Oncology 9, 2023 (suppl 1; abstr 59)

DOI

10.1200/GO.2023.9.Supplement_1.59

Abstract #

59

Poster Bd #

A1

Abstract Disclosures

Funded by Conquer Cancer

Similar Abstracts

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Role of proton pump inhibitors in immune checkpoint inhibitor colitis.

First Author: Roshini Pradeep

First Author: Elio Adib

Abstract

2023 ASCO Annual Meeting

CD57+CD8+ T cells and response to PD-1/PD-L1 blockade in patients with NSCLC.

First Author: Jianya Zhou